Back to News
Market Impact: 0.2
MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Dose First Patient in Global Phase I/II Trial of JR-446 for Mucopolysaccharidosis Type IIIB
Source: businesswire.com
Healthcare & Biotech
JCR and MEDIPAL announced that the first participant has been dosed in a global Phase I/II trial of JR-446 for mucopolysaccharidosis type IIIB. The milestone advances clinical development of a potential treatment for the rare genetic disorder, though no efficacy or safety data were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- J&J's potential 'game-changer' drug — plus, what Microsoft's mass buyouts mean
- The excitement around Moderna’s cancer vaccine is cooling. Here’s why.
- Cramer: I asked some tech insiders what to buy. They surprisingly said this drug stock
- Moderna CEO Sees Cancer Vaccines Working Beyond Melanoma
- Genmab shares jump 13% on colorectal cancer drug trial results
- Bottoms Says Georgia Needs Pause on New Data Centers